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Abstract
Statins reduce cholesterol biosynthesis by inhibiting HMG-CoA reductase and thereby lower total
cholesterol and LDL cholesterol levels in serum, which in turn lower the incidence of
cardiovascular disease (CVD). Statins are also known to modulate various cellular functions such
as gene expression, cell proliferation, and programmed cell death through inhibition of downstream
intermediates in cholesterol synthesis. In this study, we have investigated the possible effects of
statins on the secretion of serum albumin from cultured HepG2 cells since high levels of serum
albumin are associated with reduced risks for CVD and statins are effective in lowering the risk of
CVD through other effects in addition to their effects on serum total cholesterol and LDL
cholesterol levels, known as pleiotropic effects. Our results showed that simvastatin increased HSA
secretion up to 32.3% compared to the control group. Among 3 statin analogs we tested,
simvastatin exhibited the highest stimulatory effects on HSA secretion compared to the control
group. Our study also showed that the increased HSA secretions from HepG2 cells by simvastatin
treatments were due to the increased rate of HSA synthesis, not due to the reduced
posttranslational degradation rate of HSA. Our finding suggests another added benefit of statins'
treatments in preventing CVD through stimulation of HSA biosynthesis.
Background
Statins are one of the most widely prescribed medications
to patients in the high-risk group of developing CVDs to
lower total serum and LDL cholesterol levels. Statins
inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase in the cholesterol biosynthesis, thereby
lowering serum LDL cholesterol production, up-regulat-
ing the synthesis of LDL receptors in the liver, and in turn
resulting in decreased levels of circulating total cholester-
ols[1]. In addition to their major effects on serum LDL
cholesterol, recent studies have shown that statins also
exert wide variety of other effects on cellular metabolism.
These other effects of statins, known as pleiotropic effects
include modulation of gene expression, reduction of
endothelial dysfunction, inhibition of inflammatory reac-
tions, antioxidant effects, inhibition of smooth muscle
proliferation, and induction of apoptosis [2-9]. These
findings suggest that the overall cardioprotective effects of
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statin treatments resulted not only from the decreased
serum LDL cholesterol level but also from statins' poten-
tial pleiotropic effects. In fact, several studies have sug-
gested that statins' pleiotropic effects may provide greater
protection against pathogenesis of CVDs than their cho-
lesterol lowering effects do [10,11].
Human serum albumin (HSA) is the principal carrier of
unesterified free fatty acids in serum and its major func-
tions include maintaining osmotic pressure, transporting
endogenous and exogenous ligands. Many epidemiologi-
cal studies have shown that high plasma levels of HSA are
also associated with reduced risks for CVD [12-19]. Our
previous study has shown that HSA participates in the
cholesterol efflux from cultured endothelial cells and due
to its high concentration (40 g/L) in plasma, HSA may
contribute significantly to cholesterol efflux together with
HDL mediated cholesterol efflux [20]. Other contribution
of HSA's anti-atherogenic effects might be due to its anti-
oxidant properties. HSA serves as an important antioxi-
dant in the plasma because of its free cysteine residue at
amino acid position 34 [21]. Previous study has shown
that the occurrence of oxidized LDLs (ox-LDLs) can be
attributed to the reduced synthesis of HSA that is often
observed in hypercholesterolemia and diabetes patients
[22]. Therefore, antioxidant capacity of the body fluids
may significantly be affected by changes in the concentra-
tion of serum albumin. Many of HSA's anti-atherogenic
functions overlap with statins' cardioprotective effects in
the body. Therefore, in the present study we investigated
whether statin's effects include the modulation of albu-
min synthesis and secretion from the cultured HepG2
cells since previous studies have shown that statins effects
in cellular level include the modulation of certain gene
expression.
The structure of HMG-CoA reductase and complexes with
six statins have been determined by X-ray crystallographic
studies [23]. All statins function similarly by binding to
the active site of HMG-CoA reductase and thus inhibiting
the enzyme reaction. However, the different structures
and binding characteristics of statins are responsible for
the differences in potency of HMG-Co A reductase inhibi-
tion and other variations in pharmacologic properties
[23-25]. Since all of the statins inhibit HMG-CoA reduct-
ase with minor differences in their effects, their pleio-
tropic effects might also be different among statins. In the
present study, we compared the effects of three statin ana-
logs, simvastatin, lovastatin, and pravastatin on HSA
secretion from HepG2 cells.
Materials and methods
Materials
Human hepatoma HepG2 cells (HB8065) were obtained
from American Type Culture Collection (Rockville, MD).
Cell culture media (RPMI 1640) and fetal bovine serum
(FBS) were obtained from Invitrogen Life Technologies
(Grand Island, NY). Culture dishes were obtained from
Corning Costar (Lowell, MA). Prestained SDS-PAGE
Standard, Affi-Gel Protein A was from Bio-Rad (Hercules,
CA). Simvastatin, lovastatin, pravastatin and anti-Human
albumin antibody were from Sigma (St. Louis, MO). [35S]
protein-labeling mix was from Perkin Elmer Life Science
Research Products (Boston, MA). ENHANCE™ and autora-
diography films were purchased from NEN Life Science
Research Products (Boston, MA). RNeasy Mini Kit and
Onestep RT-PCR kit were obtained from Qiagen (Valen-
cia, CA). Human Albumin ELISA Quantitation Kit was
obtained Bethyl Inc. (Montgomery, TX). Oligonucleotide
primers for RT-PCR for HSA and GAPDH genes were from
Midland Certified Reagent (Midland, TX).
Cell Culture
HepG2 cells were maintained in RPMI medium supple-
mented with 10% fetal bovine serum (FBS), 1% glycine,
and 1% antibiotics at 37°C as previously described [26].
Cell cultures were allowed to reach 90% confluency. The
cells were then treated with appropriate culture media
containing 100 nM to 10 M of simvastatin, lovastatin,
and pravastatin and incubated at 37°C for 24 hours.
Secretion of HSA measured by ELISA
The amount of HSA secreted into the culture medium was
determined by Human Albumin ELISA Kit. Spectrophoto-
metric measurements were made by using a Microplate
reader (VERSAmax, Molecular Devices, CA). Cells treated
with or without statins were harvested and lysed in 0.5 ml
of 0.1 N NaOH solution. The total cellular protein con-
tents were measured by bicinchoninic acid (BCA) Protein
Assay Kit (Pierce Chemical, Rockford, IL).
HSA synthesis measured by incorporation of [35S]
The effects of simvastatin on the synthesis/secretion of
HSA in HepG2 cells were studied by measuring the
amount of [35S] radiolabeled methionine incorporated
into HSA, which was secreted into the culture medium.
HepG2 cells were incubated in methionine/cysteine free
RPMI medium containing simvastatin and [35S] methio-
nine/cysteine (100 Ci/ml) for 20 minute. After labeling,
the radioactivity was chased for 1 h and then, the culture
medium and cell lysates were subjected to the measure-
ment of HSA concentration.
Pulse-Chase Analysis of HSA Synthesis and Secretion
To determine whether effects of statins on HSA secretion
were due to altered synthesis rate or due to changed post-
translational degradation rate, the amount of HSA de novo
synthesis was measured by a modified pulse-chase
method as previously described by Theriault et al. [27]. To
determine the amount of de novo HSA biosynthesis, cellsJournal of Biomedical Science 2009, 16:32 http://www.jbiomedsci.com/content/16/1/32
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were preincubated in methionine and cysteine free RPMI
media with or without statins for 30 minutes. After prein-
cubation, cells were pulsed with a [35S] methionine/
cysteine-labeling medium supplemented with 100 Ci/
ml [35S] methionine/cysteine (Perkin Elmer, Waltham,
MA), in methionine and cysteine-free RPMI for 20 min-
utes. After the pulse treatment, the cells were washed with
PBS two times and placed in the chase medium contain-
ing 1000-fold excess unlabeled methionine/cysteine for
20 & 120 minutes in the presence of various statins. At
each chase time, the cells were harvested and lysed in PBS
buffer containing 1% NP40, 1% deoxycholate, 5 mmole/
L EDTA, and 1 mmole/L EGTA. The lysates were centri-
fuged for 10 minutes in a microcentrifuge at 10,000 rpm
for immunoprecipitation and analyzed by SDS-PAGE and
fluorography as described previously [27].
Measurement of HSA mRNA expression
To determine mRNA synthesis levels in the cells, total
RNA was extracted by RNeasy Kit (Qiagen, CA) and was
subjected to RT-PCR reactions by using a commercial Qia-
gen Onestep RT-PCR Kit (Qiagen, CA). The glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) was used as
a control for RT-PCR reactions. The RT-PCR products of
HSA and GAPDH mRNA were analyzed on 2% agarose gel
electrophoresis using ethidium bromide staining. DNA
band intensities were determined by Gel Documentation
System (Bio-Rad Laboratories, Hercules, CA). Using the
amount of GAPDH mRNA amplified as control, the
mRNA levels of HSA were normalized and compared.
Statistical analysis
All data were expressed as the mean ± SD of at least three
experiments performed in duplicate. Differences between
group means were analyzed by using Student t-tests.
Results
Determination of optimal simvastatin concentration for 
the study of statins' effects on HepG2 cells
To determine the optimal conditions for the analysis of
statins' effects on cell culture, HepG2 cells were incubated
with various concentrations of simvastatin (0, 0.5, 1.0, 5,
10 M) for 24 hours. The treatments of 0.5, 1.0, 5, and 10
M simvastatin increased HSA secretion up to 31.2, 32.3,
20.3, and 13.1%, respectively compared to control group
cells without simvastatin treatments. The maximum effect
on HSA secretion was observed with 1 M simvastatin
added to the culture medium (Fig. 1). Further increases in
the concentration of simvastatin did not enhance its stim-
ulatory effect on HSA secretion from HepG2 cells. There-
fore, we used 1 M and 5 M simvastatin concentrations
for our study. Also, incubation time of 24 hours did not
alter either the morphology or viability of HepG2 cells.
Effects of simvastatin, lovastatin and pravastatin on HSA 
secretion
The stimulatory effect of simvastatin on HSA secretion
from HepG2 cells was compared with those of lovastatin
and pravastatin. As seen in Fig. 2, three statin analogs
showed different effects on HSA secretion in dose depend-
ent experiments. Lovastatin had the minimal effects and
pravastatin increased HSA secretion only at high concen-
trations (13%, 5 M; 19%, 10 M) (Fig 2). Among these
statin analogs, simvastatin showed the highest increase in
HSA secretion and was chosen for the further studies.
Time-dependent effect of simvastatin on HSA secretion
To determine the optimal incubation time for our study,
we tested statins' effects on HSA secretion with different
incubation times (3, 6, 12, 24, 36, and 48 hours). Among
these different time settings, statins' effects on HSA secre-
tion reached the maximum rate at 24 hours of incubation
time. Therefore, for all further experiments we used 24-
hour incubation time (Fig. 3).
Simvastatin increases synthesis and secretion of HSA in 
HepG2 cells
The effect of simvastatin on de novo synthesis of HSA was
determined by incubating cells with [35S] methionine for
22 hours in the presence of 1 or 5 M of simvastatin. De
novo synthesis of HSA was determined by immunoprecip-
itation and radioactivity measurement. As shown in Fig 4,
the level of HSA synthesis in the presence or absence of 1
and 5 M of simvastatin was affected. There was a signifi-
cant increase in the intracellular levels of HSA. In the pres-
ence of 1 and 5 M simvastatin, de novo synthesis of HSA
was increased by 37% and 33%, respectively.
Measurement of HSA secreted into the culture media after
2 hours of incubation with simvastatin in HepG2 cells
showed that pretreatment with 1 M simvastatin induced
a smaller but significant stimulation (~20%) of HSA
secretion. However, treatment of 5 M simvastatin had no
apparent effects on HSA secretion when compared to the
treatment of 1 M simvastatin as shown in Fig. 5. The data
suggest that treatment of 1 M simvastatin induced the
increases in both de novo synthesis and secretion of HSA
into the medium. However, 5 M simvastatin treatment
increased de novo synthesis of HSA but not HSA secretion
into the medium.
Simvastatin effects on total protein synthesis
To determine whether simvastatin specifically increased
de novo synthesis of HSA, total protein synthesis of HepG2
cells was examined after 2-hour incubation with [35S]
methionine/cysteine by TCA precipitation. The cells were
treated with 1 M and 5 M of simvastatin for 22 hours.
The results showed that there was 13% increase in total
protein synthesis in simvastatin treated cells compared toJournal of Biomedical Science 2009, 16:32 http://www.jbiomedsci.com/content/16/1/32
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the control group. However, different amounts of simvas-
tatin treatment (1 M and 5 M) did not show differences
in total protein synthesis change (Fig. 6).
Simvastatin effects on intracellular turnover rate of HSA
A modified pulse-chase labeling experiment was per-
formed to determine whether the effect of simvastatin on
HepG2 cells was due to the increased synthesis of HSA or
the decreased post-translational degradation level of HSA.
The result showed that incorporation rates of [35S]-
methionine into HSA during the pulse was higher in cells
preincubated with simvastatin than control cells preincu-
bated without simvastatin. After 2 hours of chase incuba-
tion, HSA secretion into the medium was determined and
the results showed that there were no significant changes
in HSA degradation in the cells treated with or without 1
M simvastatin. However, the cells treated with 5 M of
simvastatin induced the increased degradation of HSA
compared to the cells without simvastatin treatment
(Table 1). The increased HSA degradation rate by 5 M
simvastatin treatment explains that HSA secretion from
the cells treated with 5 M simvastatin was not changed
significantly compared to the control cells without simv-
astatin treatment. Simvastatin treatment to the cultured
HepG2 cells lead to the increased synthesis of HSA and at
higher concentration the treatment induced both HSA
synthesis increase and degradation.
Simvastatin effects on HSA mRNA levels in HepG2 cells
To confirm the increased HSA synthesis in the presence of
simvastatin, we used RT-PCR technique to measure the
changes in the intracellular levels of HSA mRNA synthesis.
The results indicated that the cells treated with 1 and 5 M
of simvastatin showed that HSA mRNA synthesis was
increased by 13.6% and 6%, respectively compared to the
level of HSA mRNA synthesis of control cells without
treatment of simvastatin (Fig 7). This result further vali-
dates our findings that the effects of simvastatin on HSA
secretion were mainly due to increased synthesis of HSA
in the cells treated with simvastatin, not the results of
reduced degradation of HSA.
Discussion
Statins have been widely prescribed to treat hypercholes-
terolemia in an effort to reduce the risk of developing
CVDs. A number of studies on statins' effects on choles-
Effects of simvastatin on HSA secretion from HepG2 cells Figure 1
Effects of simvastatin on HSA secretion from HepG2 cells. Cells were exposed to various concentrations (0, 0.5, 1, 5, 
10 M) of simvastatin for 24 hours. HSA secretion was measured by ELISA. Data presented are mean ± SD from three inde-
pendent experiments performed in triplicate. *P < 0.05, **P < 0.01 vs. without simvastatin.Journal of Biomedical Science 2009, 16:32 http://www.jbiomedsci.com/content/16/1/32
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terol metabolism provided solid evidence that statins are
very effective in lowering serum LDL cholesterol levels,
thereby reducing the incidence of CVD cases. Many stud-
ies have shown that other effects of statins includes non-
lipid related physiologic effects such as down-regulation
of cell adhesion molecule expressions, angiotensin-con-
verting enzyme (ACE) gene expression, endothelin-1
receptor expression and C-reactive protein expression [28-
32]. These other effects of statins, so called pleiotropic
effects also included up-regulation of certain genes such as
collagen gene expression. These studies on statins' effects
on various metabolic pathways suggested that statins not
only served as major inhibitors for HMG-CoA reductase in
cholesterol synthesis but also served as major metabolic
modulators on the expression of various other metabo-
lites, which participate in other distinctive processes in the
body.
Albumin is the major plasma protein, which mainly
responsible for maintaining oncotic pressure of plasma.
Another main function of albumin in circulation includes
transportation of major endogenous and exogenous
metabolites and compounds such as thyroxine, bilirubin,
free fatty acids, digoxin, ibuprofen. However, recent stud-
ies on albumin's other functions revealed that albumin
plays an important role in the pathogenesis of cardiovas-
cular diseases. Previous epidemiological studies have
shown that the levels of HSA in the serum can be served
Effects of simvastatin, lovastatin and pravastatin on HSA secretion Figure 2
Effects of simvastatin, lovastatin and pravastatin on HSA secretion. Cells were exposed to different concentrations 
(0, 0.5, 1, 5, 10 M) of simvastatin, lovastatin and pravastatin for 24 hours. HSA secretion was measured by ELISA. Data are 
mean ± SD from three independent experiments performed in triplicate.Journal of Biomedical Science 2009, 16:32 http://www.jbiomedsci.com/content/16/1/32
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Time-dependent effect of simvastatin on HSA secretion in HepG2 cells Figure 3
Time-dependent effect of simvastatin on HSA secretion in HepG2 cells. Cells were treated with 1 M of simvastatin 
for 3, 6, 12, 24, and 48 hours and then HSA was measured by ELISA. Values represent the mean ± SD from three independent 
experiments performed in triplicate.
Effects of simvastatin treatments on intracellular HSA synthesis in HepG2 cells Figure 4
Effects of simvastatin treatments on intracellular HSA synthesis in HepG2 cells. HepG2 cells were treated with 0, 
1, and 5 M simvastatin for 22 hours and further incubated with [35S]-methionine. After incubation, cells were lysed with lysis 
buffer and the resulting cell lysates were subjected to immunoprecipitation. Cell lystaes were further analyzed by SDS-PAGE/
Fluorography and radioactivity of HSA protein bands were quantified by liquid scintillation counting. Data are mean ± SD from 
three independent experiments performed in duplicate. *P < 0.05 vs. without simvastatin.Journal of Biomedical Science 2009, 16:32 http://www.jbiomedsci.com/content/16/1/32
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Effects of simvastatin treatment on HSA secretion into culture media from HepG2 cells Figure 5
Effects of simvastatin treatment on HSA secretion into culture media from HepG2 cells. HepG2 cells were 
treated with 0, 1, and 5 M simvastatin for 22 hours in RPMI media. Cells were incubated additional 2 hours with [35S]-methio-
nine/cysteine. Media was collected and the secreted HSA in the media was immunoprecipitated with a specific anti-HSA anti-
body followed by SDS-PAGE. Radioactive quantification of HSA bands was performed by liquid scintillation counting. Data are 
mean ± SD from three independent experiments performed in triplicate. *P < 0.05 vs. without simvastatin.
Effects of simvastatin on total radiolabeled protein in HepG2 cells Figure 6
Effects of simvastatin on total radiolabeled protein in HepG2 cells. Confluent HepG2 cells were treated with 1 and 5 
M simvastatin for 22 hours and then labeled for 2 hours with [35S]-methionine/cysteine. Total protein was determined by 
TCA precipitation. Data are mean ± SD from three independent experiments performed in triplicate. *P < 0.05 vs. without 
simvastatin.Journal of Biomedical Science 2009, 16:32 http://www.jbiomedsci.com/content/16/1/32
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 an independent risk factor for mortality and morbidity
[17,33,34]. Also, it was shown that HSA possesses cardio-
protective function and its high levels in serum were cor-
related with lowered incidence of CHD [19].
Furthermore, HSA participates in cholesterol efflux from
peripheral tissues and contributes to the overall choles-
terol efflux along with the contributions from HDL. In
rodents, one study suggested that albumin contributes up
to 24% of non-esterified cholesterol transport due to its
high concentration in serum (35 – 50 grams/liter)
[20,35]. Since many studies have shown that statins pos-
sess non-lipid pleiotropic effects on other metabolite
expressions, we hypothesized that statins may also affect
the level of HSA synthesis in the hepatocytes. In this study,
we chose to investigate the effects of statins on HSA syn-
thesis and secretion by using cultured HepG2 cells.
Our study showed that statins increased albumin secre-
tion rate in cultured HepG2 cells by as much as 30%. We
found that among three different analogs of statin, simv-
astatin showed the most significant effects on HSA secre-
tion at concentrations ranges from 0.5 to 5 M. These
results indicate that the effect of statins on albumin secre-
tion may complement to the effectiveness of statins' cho-
lesterol lowering capacity. Furthermore, previous clinical
studies showed that the mean reductions in total choles-
terol in simvastatin treated group were highest (25%)
compared to lovastatin treated group (17%) and pravasta-
tin treated group (20%) [36]. The stimulation of albumin
secretion by statins might be due to the inhibition of Ras-
mediated signal transduction pathway in the regulation of
hepatic cell growth by inhibiting mevalonate synthesis,
thereby inhibiting posttranslational modification of Ras
proteins. Statins are known to inhibit Ras farnesylation,
resulting in the accumulation of inactive Ras proteins in
the cytoplasm [37]. Previous study has shown that Ras
proteins suppress albumin enhancer function possibly
mediated through AP-1 interaction and therefore, inhibi-
tion of Ras proteins should result in increased expression
of HSA synthesis [38].
The physiological processes between albumin synthesis
and degradation maintain serum albumin concentration.
Measurement of albumin synthesis rate should provide
more dynamic insight into the effects of statin and its ana-
logs on modulation of albumin metabolism than meas-
urement of albumin degradation rate. To test this
hypothesis, we used ELISA technique to measure secreted
albumin and RT-PCR method to quantify albumin mRNA
synthesis.
Table 1: Effects of simvastatin on intracellular HSA degradation 
in HepG2 cells.
HSA (102 × dpm)
Control Simvastatin (1 M) Simvastatin (5 M)
Intra peak * 350 ± 31 414 ± 24 403 ± 52
Depletion 216 237 243
Secretion 168 173 143
Degradation 48 64 100
% Recovery ** 86.3 84.5 75.2
Cells were incubated for 22 hours with 0, 1, and 5 M simvastatin, 
then cell were pulse-labeled for 20 minutes with [35S] methionine. 
After pulse-labeling, media were washed and incubated for 20, 120 
minutes in media containing an excess of unlabeled methionine/
cysteine. At the end of each chase period, solubilized cell lysates and 
media were subjected to immunoprecipitation. Quantification of 
labeled HSA was determined by SDS-PAGE and scintillation counting. 
Data presented are from three separate experiments done in 
duplicate.
* Intra peaks were calculated from the HSA content at 20 minutes of 
chase
** % recovery represents total labeled apoB (cell lysate + media) 
remained after 2-hour chasing.
Effects of simvastatin on HSA mRNA expression in HepG2  cells Figure 7
Effects of simvastatin on HSA mRNA expression in 
HepG2 cells. HepG2 cells were treated with 0, 1, 5 M sim-
vastatin for 22 hours. Total RNA was isolated and RT-PCR 
was subjected. HSA mRNA levels were quantified as 
described in Methods. Each band density of HSA was normal-
ized by GAPDH and expressed as ratio of HSA mRNA to 
GAPDH mRNA. Bottom panels are representative of four 
independent experiments. Bar graph is mean ± SD from 
these experimentsJournal of Biomedical Science 2009, 16:32 http://www.jbiomedsci.com/content/16/1/32
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Our results showed that 1 M simvastatin showed 30%
increase in HSA secretion compared to control group and
13.6% increase in HSA mRNA synthesis. The 30%
increase in HSA secretion from HepG2 cells incubated in
the presence of 1 M simvastatin could be accounted by
13.6% increase in HSA mRNA synthesis since one mole-
cule of mRNA is used for the synthesis of many molecules
of HSA. To validate our findings on simvastatin effects on
HSA secretion, we determined total protein synthesis in
the cultured HepG2 cells in the presence of 1 and 5 M
simvastatin and showed that 1 and 5 M simvastatin
increased 11% and 13% of total protein synthesis. These
findings imply that simvastatin's effects on HSA secretion
was not through increasing total protein synthesis of
HepG2 cells, rather simvastatin's effects on HSA synthesis
was specific process.
Various concentrations of pravastatin showed dose-
dependent effects on HSA secretion whereas the effects of
lovastatin showed dose-independent effects on albumin
secretion. However, simvastatin has shown a biphasic
effects in HSA secretions. The cells treated with 1 M sim-
vastatin showed better stimulation in HSA secretions
(32.3%) compared to the cells treated with 5 M simvas-
tatin (13.1%). The differences in HSA secretions at two
different simvastatin concentrations correspond to the
different effects on HSA mRNA synthesis in HepG2 cells
(Fig 7). This suggests that simvastatin's effects on HSA syn-
thesis might be through regulation at the transcriptional
level.
To further confirm the simvastatin's effects on HSA syn-
thesis, we used [35S] incorporation technique to test the
30% increase in HSA secretion was the result of new HSA
protein synthesis, not the result of reduced degradation of
HSA in the cells. Our results clearly indicated that new
synthesis of HSA was responsible for the increased HSA
synthesis under the treatment of simvastatin. Also, studies
on the degradation rate of HSA in the presence of simvas-
tatin showed that there were no apparent changes in the
intracellular degradation of HSA. In toto, our results spe-
cifically suggest that simvastatin induces increased HSA
gene expression and results in increased HSA secretion
from HepG2 cells. These findings add another beneficial
effect of simvastatin treatment to the growing number of
known benefits of HMG-CoA inhibitor treatments.
Increased in HSA synthesis under the influence of simvas-
tatin may provide synergic effects of simvastatin in lower-
ing risk factors for developing CHD since previous
epidemiologic studies have shown that high HSA levels
are associated with reduced risk for these diseases. The
mechanism of simvastatin effects on up-regulation of HSA
synthesis needs further studies.
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